new9 Antibody

What is new9 Antibody and what organism does it target?

New9 Antibody is a polyclonal antibody raised in rabbit against recombinant Schizosaccharomyces pombe (strain 972 / ATCC 24843) new9 protein. The antibody specifically targets the new9 protein (UniProt accession number: G2TRN2) in fission yeast samples . This antibody is particularly valuable for researchers studying gene expression patterns, protein-protein interactions, and cellular processes in S. pombe model systems. As a polyclonal antibody, it recognizes multiple epitopes on the target protein, potentially offering robust detection capabilities across various experimental conditions.

What are the validated applications for new9 Antibody?

The new9 Antibody has been validated for the following research applications:

These applications allow researchers to detect and quantify new9 protein expression in various experimental contexts, supporting both functional and structural studies of fission yeast biology . The antibody has been specifically validated to ensure identification of the target antigen.

What are the key specifications and physical properties?

New9 Antibody has the following specifications:

• Product Code: CSB-PA522298XA01SXV

• Uniprot Accession: G2TRN2

• Immunogen: Recombinant S. pombe (strain 972 / ATCC 24843) new9 protein

• Host Species: Rabbit

• Species Reactivity: S. pombe (strain 972 / ATCC 24843)

• Form: Liquid

• Conjugate Type: Non-conjugated

• Storage Buffer: 0.03% Proclin 300, 50% Glycerol, 0.01M PBS, pH 7.4

• Purification Method: Antigen Affinity Purified

• Isotype: IgG

• Clonality: Polyclonal

• Lead Time: Made-to-order (14-16 weeks)

These specifications provide researchers with the fundamental information needed to properly incorporate this antibody into experimental designs.

How should new9 Antibody be stored and handled?

Optimal storage conditions for new9 Antibody include maintaining the product at either -20°C or -80°C upon receipt . Researchers should avoid repeated freeze-thaw cycles as this can degrade antibody quality and compromise experimental results. The antibody is supplied in a storage buffer containing 50% glycerol, which helps maintain stability during freeze-thaw transitions. When working with the antibody, it is advisable to aliquot the stock solution to minimize the need for repeated freezing of the entire volume. Proper handling procedures include maintaining sterile technique when accessing the antibody solution and ensuring all pipetting equipment is free from contamination.

What experimental design considerations should be implemented when using new9 Antibody?

When designing experiments with new9 Antibody, researchers should consider several critical factors:

• Appropriate controls: Include both positive controls (known samples containing the target protein) and negative controls (samples lacking the target or isotype controls) to validate specificity.

• Cross-reactivity assessment: Although the antibody is designed for S. pombe specificity, preliminary tests should evaluate potential cross-reactivity with proteins from other organisms if working in complex systems.

• Optimization protocols: Titration experiments should be conducted to determine optimal antibody concentration for each specific application.

• Sample preparation optimization: For fission yeast samples, optimization of cell lysis methods is crucial to ensure adequate protein extraction while preserving epitope integrity. Mechanical disruption methods often yield better results with yeast cell walls compared to chemical lysis alone.

• Detection system compatibility: Ensure secondary antibody systems are compatible with rabbit-derived primary antibodies and optimize signal-to-noise ratios through preliminary testing.

When performing Western blot analysis, particular attention should be paid to transfer conditions, as some yeast proteins may require extended transfer times or specialized buffers to achieve optimal membrane binding.

How can researchers troubleshoot non-specific binding or weak signals?

Non-specific binding and weak signals represent common challenges when working with antibodies in fission yeast research. Troubleshooting approaches include:

• Blocking optimization: Test different blocking agents (BSA, milk, commercial blockers) and concentrations to reduce background.

• Antibody concentration adjustment: Titrate antibody dilutions to identify optimal concentration that maximizes specific signal while minimizing background.

• Incubation conditions: Modify temperature, duration, and buffer composition during antibody incubation steps.

• Sample preparation refinement: Ensure complete cell lysis and consider including protease inhibitors to prevent target degradation.

• Enhanced detection systems: For weak signals, explore signal amplification methods such as biotin-streptavidin systems or more sensitive chemiluminescent substrates.

• Epitope masking assessment: If signals are consistently weak, consider whether post-translational modifications or protein-protein interactions might be masking the epitope recognized by the antibody.

Maintaining detailed laboratory records of optimization steps will facilitate systematic troubleshooting and improve reproducibility across experiments.

What are the methodological considerations for detecting low-abundance new9 protein?

Detecting low-abundance proteins in fission yeast presents specific challenges that require methodological adaptations:

• Sample enrichment: Consider subcellular fractionation or immunoprecipitation to concentrate the target protein before analysis.

• Signal amplification: Implement high-sensitivity detection systems such as enhanced chemiluminescence or fluorescent secondary antibodies.

• Increased sample loading: Optimize protein loading amounts while monitoring for potential lane distortion or resolution issues.

• Extended exposure times: For Western blots, longer exposure times may reveal low-abundance signals, though care must be taken to monitor increasing background.

• Protein precipitation techniques: TCA precipitation or similar methods can concentrate proteins from dilute samples.

• Reducing sample complexity: Using size exclusion chromatography or other fractionation methods prior to immunodetection can improve signal-to-noise ratio for low-abundance targets.

These methodological adaptations should be systematically evaluated and documented to establish optimal detection protocols for specific experimental contexts.

How does protein extraction methodology affect new9 Antibody performance?

The choice of protein extraction method significantly impacts new9 Antibody performance when working with fission yeast:

• Cell wall disruption efficiency: S. pombe has a robust cell wall requiring effective disruption methods. Mechanical disruption using glass beads or enzymatic approaches with lyticase/zymolyase typically yield superior results compared to detergent-only methods.

• Buffer composition effects: Extraction buffers containing high detergent concentrations may modify protein conformation, potentially affecting epitope recognition. Testing multiple buffer compositions is recommended.

• Protein solubilization challenges: Some yeast proteins may partition into different fractions based on solubility. A systematic comparison of soluble and membrane-associated fractions may be necessary to locate the target protein.

• Protease inhibition requirements: Yeast extracts often contain active proteases that can degrade target proteins during extraction. Comprehensive protease inhibitor cocktails are essential.

• Native versus denaturing conditions: Depending on the experimental goals, maintaining native protein conformation or ensuring complete denaturation will require different extraction approaches, potentially affecting antibody recognition.

Optimization of extraction methodology should be considered a critical preliminary step in experimental design when working with new9 Antibody.

What protocol modifications are recommended for Western blot applications?

For optimal Western blot results with new9 Antibody in fission yeast research:

• Sample preparation: Use glass bead lysis in buffer containing 50mM Tris-HCl pH 7.5, 150mM NaCl, 1% Triton X-100, 1mM EDTA, and protease inhibitor cocktail.

• Gel percentage optimization: 10-12% polyacrylamide gels typically provide optimal resolution for new9 protein.

• Transfer conditions: Use wet transfer at 30V overnight at 4°C to ensure complete transfer of yeast proteins.

• Blocking recommendations: 5% non-fat dry milk in TBST for 1 hour at room temperature generally provides optimal blocking.

• Antibody incubation: Start with 1:1000 dilution in blocking buffer overnight at 4°C, then optimize based on results.

• Washing stringency: Implement 5 washes of 5 minutes each with TBST to reduce background while preserving specific signals.

• Secondary antibody: Anti-rabbit HRP conjugated antibody at 1:5000 dilution for 1 hour at room temperature.

• Detection system: Enhanced chemiluminescence systems provide good sensitivity for most applications.

Each laboratory should validate these recommendations with their specific samples and equipment configurations.

How should ELISA protocols be adapted for new9 Antibody?

When developing ELISA protocols with new9 Antibody:

• Plate coating: Use purified recombinant new9 protein at 1-10 μg/mL in carbonate buffer (pH 9.6) overnight at 4°C for direct ELISA, or capture antibody for sandwich ELISA.

• Blocking conditions: 2% BSA in PBST for 2 hours at room temperature typically provides effective blocking.

• Sample preparation: For cell lysates, use non-denaturing extraction buffers compatible with ELISA applications.

• Antibody dilution series: Prepare a dilution series (1:500 to 1:10,000) to determine optimal concentration for specific sample types.

• Incubation conditions: 2 hours at room temperature or overnight at 4°C, with gentle shaking for optimal binding.

• Detection system selection: HRP-conjugated secondary antibodies with TMB substrate provide good sensitivity with colorimetric readout.

• Standard curve generation: If quantifying new9 protein, prepare standards with purified recombinant protein at known concentrations.

These methodological adaptations provide a starting point for ELISA development, which should be validated and refined for specific research applications.

What cross-validation approaches confirm new9 Antibody specificity?

To ensure experimental rigor, researchers should implement multiple approaches to validate antibody specificity:

• Genetic controls: Compare wild-type S. pombe with new9 deletion or knockdown strains to confirm signal specificity.

• Peptide competition assays: Pre-incubate antibody with excess immunizing peptide or recombinant new9 protein to demonstrate specific signal blocking.

• Orthogonal detection methods: Confirm results using alternative methods such as mass spectrometry or RNA expression analysis.

• Tag-based validation: If possible, compare antibody detection with epitope-tagged new9 protein detected via anti-tag antibodies.

• Immunoprecipitation followed by mass spectrometry: Confirm that immunoprecipitated proteins contain the expected new9 peptides.

• Multiple antibody comparison: If available, compare results with other antibodies targeting different epitopes of the same protein.

Implementing these validation approaches increases confidence in experimental results and addresses potential concerns regarding antibody specificity.

How can new9 Antibody contribute to understanding fission yeast cellular biology?

New9 Antibody enables various research applications that advance understanding of fission yeast biology:

• Protein expression analysis: Monitor new9 protein levels under various growth conditions or stress responses.

• Subcellular localization studies: When adapted for immunofluorescence, the antibody can help determine the intracellular distribution of new9 protein.

• Protein-protein interaction studies: Use in co-immunoprecipitation experiments to identify binding partners.

• Post-translational modification analysis: Detect changes in new9 protein modifications under different cellular conditions.

• Cell cycle regulation studies: Examine how new9 protein levels or modifications change throughout the cell cycle.

• Comparative analysis across yeast strains: Investigate strain-specific variations in new9 protein expression or function.

These applications contribute to broader understanding of cellular processes in this important model organism.

What emerging technologies might enhance new9 Antibody applications?

Several advanced technologies could expand the utility of new9 Antibody in research:

• Super-resolution microscopy: Adaptation of the antibody for techniques like STORM or PALM could provide nanoscale insights into new9 protein localization.

• Proximity labeling approaches: Combining new9 Antibody with BioID or APEX systems could map the protein's interaction neighborhood.

• Single-cell proteomics: Emerging single-cell protein analysis methods could reveal cell-to-cell variability in new9 expression.

• Microfluidic antibody arrays: Integration with microfluidic systems could enable high-throughput screening of new9 expression under numerous conditions.

• Quantitative multiplexed immunofluorescence: Simultaneous detection of new9 with multiple other proteins could provide systems-level insights.

• CRISPR-based knock-in validation: CRISPR technology enables precise epitope tagging for antibody validation and enhanced detection sensitivity.

Researchers should monitor technological developments that might be adapted to extend the capabilities of this antibody in future studies.

What are the current limitations in new9 Antibody research applications?

Understanding current limitations helps researchers design appropriate experiments and interpret results accurately:

• Cross-reactivity characterization: Limited information is available regarding potential cross-reactivity with proteins from other organisms.

• Post-translational modification detection: Current data does not specify whether the antibody can detect modified forms of the new9 protein.

• Epitope mapping: Detailed information about specific epitopes recognized by this polyclonal antibody is not available.

• Application range limitations: While validated for ELISA and Western blot, optimization for other applications like immunohistochemistry or chromatin immunoprecipitation would require additional validation.

• Batch-to-batch variability: As a polyclonal antibody, some variation between production lots may occur, necessitating re-validation with new batches.

Acknowledging these limitations allows researchers to design appropriate controls and interpret results within the proper context.